Charterhouse completes take-private deal for Animalcare Group
Bottom line
Charterhouse Capital Partners has completed its acquisition of Animalcare Group, taking the York, England-based animal health company private after its shares were cancelled from trading on London’s AIM market on July 31, 2026. The deal was first announced on April 16, 2026, at 336 pence per share, valuing Animalcare at about £235.2 million. Animalcare said the transaction became effective after court sanction and the completion of required steps under the scheme of arrangement process. (investegate.co.uk)
Why it matters: For veterinary professionals, this is another sign that specialist animal health companies with established product portfolios, international distribution, and pipeline assets remain attractive to private equity. Animalcare brings a portfolio of about 150 brands across companion animal, equine, and production animal markets, with particular strength in pain, dental, and equine products. In recent reporting, the company highlighted revenue growth, a more own-brand-heavy sales mix, and continued investment in pipeline programs, including antibody research in osteoarthritis and pain. Going private could give management more room to invest outside public market pressures, but it also puts a closely watched supplier into private equity hands at a time when consolidation across animal health continues. (animalcaregroup.com)
What to watch: Watch for whether Charterhouse uses Animalcare as a buy-and-build platform, especially after highlighting the company’s Randlab acquisition and internal R&D pipeline as drivers for further expansion. (lse.co.uk)
Charterhouse Capital Partners has closed its acquisition of Animalcare Group, completing a deal that removes the veterinary pharmaceutical company from London’s AIM market and places it under private ownership. Animalcare confirmed that the scheme of arrangement became effective in late July, and that trading in its shares was cancelled at 7:00 a.m. on July 31, 2026. (investegate.co.uk)
The transaction had been in motion since April 16, 2026, when Animalcare and CCP Paw 2 Limited, a Charterhouse-backed bid vehicle, announced a recommended cash offer of 336 pence per share. That offer valued the company’s fully diluted share capital at roughly £235.2 million and represented a 36% premium to Animalcare’s closing share price on April 15. The deal was structured as a UK court-sanctioned scheme of arrangement, a common route for public-to-private transactions in the UK market. (lse.co.uk)
Animalcare enters private ownership as a well-established mid-cap animal health business with a broad commercial footprint. The company, headquartered in York, develops and commercializes products for companion animals, equine, and production animals, and has described its portfolio as roughly 150 brands. In its recent reporting, Animalcare pointed to momentum in key categories including pain and dental, while also emphasizing that own brands now account for about 70% of sales mix, a shift that can improve strategic control and margins. (animalcaregroup.com)
Charterhouse’s rationale appears to be more than a simple take-private. In the acquisition materials, the buyer pointed to Animalcare’s acquisition of Randlab as a model for international expansion and said the company’s internal R&D capabilities, recent launches, and pipeline create a path to further growth. Regulatory updates also show the deal moved through required approvals and conditions, including the FIRB condition referenced in June, before financing updates were disclosed in July. (lse.co.uk)
Public expert commentary on the deal itself appears limited so far, but investor and industry-facing materials frame Animalcare as an attractive platform asset rather than a turnaround story. Animalcare’s 2025 year-in-review described the business as delivering significant revenue and EBITDA growth while remaining cash generative, and Investors’ Chronicle characterized the company as a profitable veterinary pharma group heading into the bid. That doesn’t amount to independent veterinary clinical reaction, but it does suggest the transaction is being viewed through a growth-and-scale lens. (animalcaregroup.com)
Why it matters: For veterinary professionals, ownership changes at manufacturers and marketers can eventually show up in product strategy, field support, pricing discipline, distribution priorities, and acquisition activity. Animalcare is not a clinic consolidator; it’s a supplier with positions in companion animal, equine, and production animal health. Still, the same broader capital trend is in view: investors continue to target veterinary-adjacent businesses that have recurring demand, defensible brands, and room for geographic or portfolio expansion. If Charterhouse gives Animalcare more capital and a longer runway for R&D and M&A, veterinary teams could see a more acquisitive company with a deeper product push in pain, dental, and equine segments. That said, private equity ownership can also increase pressure for portfolio optimization and return on investment, which may shape which brands and markets get the most attention. (animalcaregroup.com)
There’s also a practical signal here for animal health companies across Europe: public market scale is no longer the only credible path for growth. Animalcare had already been repositioning itself through own-brand expansion, pipeline development, and the Randlab deal. Charterhouse’s move suggests those assets were valuable enough to support a take-private at a meaningful premium, even in a market that has been selective about healthcare valuations. (lse.co.uk)
What to watch: The next phase is likely to center on integration and strategy. Watch for leadership continuity, any follow-on acquisitions, expanded investment in Animalcare’s pain and osteoarthritis pipeline, and signs that Charterhouse intends to use the company as a broader animal health platform in the UK, Europe, and Australia. That last point is an inference based on Charterhouse’s stated buy-and-build logic and its emphasis on Randlab as a template for global expansion. (lse.co.uk)